Lipophilic anesthetic agents exhibit increased volumes of distribution with risk of accumulation in patients with obesity
The paper reports that excess adiposity induces drug-specific alterations in distribution, hepatic clearance, and renal elimination. Lipophilic agents show increased volumes of distribution in obese patients, leading to a risk of drug accumulation.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Lipophilic anesthetic agents exhibit increased volumes of distribution with risk of accumulation in patients with obesity The current body of evidence comprises 1 study. EvidenceHub rates the overall confidence at 32/100 (low).
The Claim
Lipophilic anesthetic agents exhibit increased volumes of distribution with risk of accumulation in patients with obesity
This conclusion is most relevant to: Patients with obesity undergoing perioperative care.
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Perioperative drug pharmacokinetics in patients with obesity. (Current opinion in clinical nutrition and metabolic care, 2026) —
How It Works
The proposed biological pathway:
- ▸Excess adiposity alters body composition and organ function
- ▸Lipophilic agents distribute into adipose tissue
- ▸Increased volume of distribution occurs
- ▸Risk of drug accumulation
Who Might Benefit
Evidence fit by population:
- ▸Patients with obesity undergoing perioperative care
Recommended Dose
N/A
Limitations & Caveats
Important context when interpreting this evidence:
- ▸The paper is a review and does not provide original quantitative data
- ▸Pharmacokinetic evidence remains limited for several commonly used drugs like ketamine, magnesium sulfate, and dexamethasone
Frequently Asked Questions
Why do lipophilic drugs accumulate in obese patients?▼
Lipophilic drugs distribute into excess adipose tissue, increasing their volume of distribution and prolonging elimination, which can lead to accumulation.
What is the recommended dosing strategy for obese patients?▼
The paper recommends an individualized approach based on pharmacokinetic principles and clinical titration, avoiding dosing based solely on total body weight for hydrophilic drugs.
Are opioids safe for obese patients?▼
The paper advises restrictive use or avoidance of opioids due to the high incidence of sleep apnea in obese patients.
Which drugs have limited pharmacokinetic data in obesity?▼
Ketamine, magnesium sulfate, and dexamethasone have limited pharmacokinetic evidence in patients with obesity.
References
- 1.Rousseleau D, De Baerdemaeker L. “Perioperative drug pharmacokinetics in patients with obesity..” Current opinion in clinical nutrition and metabolic care, 2026. PMID: 41995285 DOI: 10.1097/MCO.0000000000001225